DPP4 and type 2 diabetes mellitus: Dipeptidyl peptidase-4 (DPP-4) inhibitors, such as alogliptin, which increases incretin levels to inhibit glucagon release leading to increased insulin secretion are also a common treatment for type 2 diabetes.